HEALTH-2011.1.1-2
HEALTH-2011.1.1-2
4 projects · €23,987,346 total EU contribution (project-level) · 46 participating organizations · 12 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€23,987,346
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (13)
- UK (7)
- Netherlands (6)
- IE (5)
- BE (4)
- CH (2)
- France (2)
- IS (2)
- DK (1)
- Italy (1)
- LU (1)
- SE (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- DECODE GENETICS EHF2 projects · IS
- ROYAL COLLEGE OF SURGEONS IN IRELAND2 projects · IE
- UNIVERSITY COLLEGE LONDON2 projects · —
- AU1 projects · DK
- INSTITUT JULES BORDET1 projects · BE
- BHSCT1 projects · UK
- CANCER TRIALS IRELAND1 projects · IE
- CARDIFF UNIVERSITY1 projects · UK
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN1 projects · DE
- CONCENTRIS RESEARCH MANAGEMENT GMBH1 projects · DE
- DHT1 projects · FR
- DNAVision1 projects · BE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia CRESTAR · 279227 | FP7 | €6,000,000 | €7,994,655 | Details |
Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFY · 278659 | FP7 | €5,990,195 | €7,782,794 | Details |
Epilepsy Pharmacogenomics: delivering biomarkers for clinical use EPIPGX · 279062 | FP7 | €5,997,996 | €7,838,259 | Details |
Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer ANGIOPREDICT · 278981 | FP7 | €5,999,156 | €7,993,255 | Details |